Form 10-Q · Quarterly report
Amgen 10-Q, filed Aug 5, 2026
- Filed
- CIK
- 0000318154
- Accession no.
- 0000318154-26-000126
Summary
Amgen reported second-quarter 2026 total revenues of $10.05 billion, net income of $2.38 billion, and diluted EPS of $4.37, with product sales up 9% to $9.54 billion, and said the European Commission granted marketing authorization for IMDYLLTRA as a monotherapy for adults with extensive-stage small cell lung cancer after platinum-based chemotherapy. Amgen also said it expected volume growth for certain brands to be partly offset by net selling price declines and flagged ongoing pricing and tariff pressures, including Medicare price setting for ENBREL and Otezla and MFN-related policy actions.
Key points
- Total product sales rose 9% to $9.537 billion for the quarter ended June 30, 2026, with U.S. product sales up 11% and rest-of-world up 4%.
- Amgen said it received relief from Section 232 tariffs for about three years from December 2025 based on U.S. manufacturing investments, after an April 2026 proclamation imposed tariffs on certain patented pharmaceuticals and APIs.
- CMS selected ENBREL and Otezla for Medicare price setting beginning in 2026 and 2027; Amgen said actions it took satisfy components of the July MFN Letter and it expanded its direct-to-patient program.
- For the rest of 2026, Amgen expects volume growth from certain brands to be partially offset by net selling price declines.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. MANAGEMENT’S DISCUSSION Overview Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. We focus on areas of high unmet medical need and leverage our expertise to strive for solutions that dramatically improve people’s lives, while also reducing the social and economic burden of disease. We helped launch the biotechnology industry more than 45 years ago and have grown to be one of the world’s leading independent biotechnology companies. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.